Impaired incretin response after a mixed meal is associated with insulin resistance in nondiabetic men

Diabetes Care

Volumn 24, Issue 9, 2001, Pages 1640-1645

  Rask, Eva ^a   Olsson, Tommy ^a   Söderberg, Stefan ^a   Johnson, Owe ^a   Seckl, Jonathan ^b   Holst, Jens Juul ^c   Ahrén, Bo ^d  

^a UMEÅ UNIVERSITY HOSPITAL   (Sweden)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

^d LUND UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; GASTRIC INHIBITORY POLYPEPTIDE; GASTROINTESTINAL HORMONE; GLUCAGON; GLUCAGON LIKE PEPTIDE; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 (7 36)AMIDE; GLUCAGON-LIKE PEPTIDE 1 (7-36)AMIDE; INSULIN; PEPTIDE FRAGMENT; PROTEIN PRECURSOR;

ADULT; ARTICLE; BLOOD; BLOOD PRESSURE; BODY WEIGHT; CLINICAL TRIAL; COMPARATIVE STUDY; EATING; GLUCOSE BLOOD LEVEL; GLUCOSE CLAMP TECHNIQUE; HUMAN; INSULIN RESISTANCE; MALE; METABOLISM; MIDDLE AGED; PHYSIOLOGY; POSTPRANDIAL STATE; REGRESSION ANALYSIS; SECRETION;

ADULT; BIOLOGICAL MARKERS; BLOOD GLUCOSE; BLOOD PRESSURE; BODY WEIGHT; EATING; GASTRIC INHIBITORY POLYPEPTIDE; GASTROINTESTINAL HORMONES; GLUCAGON; GLUCAGON-LIKE PEPTIDE 1; GLUCAGON-LIKE PEPTIDES; GLUCOSE CLAMP TECHNIQUE; HUMANS; INSULIN; INSULIN RESISTANCE; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; POSTPRANDIAL PERIOD; PROTEIN PRECURSORS; REGRESSION ANALYSIS;

EID: 0035462466     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.24.9.1640     Document Type: Article

References (14)

1. Reaven GM: Pathophysiology of insulin resistance in human disease. Physiol Rev 75:473-486, 1995
2. Byrne MM, Goke B: Human studies with glucagon-like-peptide-1: potential of the gut hormone for clinical use. Diabet Med 13:854-860, 1996
3. Holst JJ, Gromada J, Nauck MA: The pathogenesis of NIDDM involves a defective expression of the GIF receptor. Diabetologia 40:984-986, 1997
4. Scrocchi LA, Brown TJ, MaClusky N, Brubaker PL, Auerbach AB, Joyner AL, Drucker DJ: Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide 1 receptor gene. Nat Med 2:1254-1258, 1996
5. Miyawaki K, Yamada Y, Yano H, Niwa H, Ban N, Ihara Y, Kubota A, Fujimoto S, Kajikawa M, Kuroe A, Tsuda K, Hashimoto H, Yamashita T, Jomori T, Tashiro F, Miyazaki J, Seino Y: Glucose intolerance caused by a defect in the enteroinsular axis: a study in gastric inhibitory polypeptide receptor knockout mice. Proc Natl Acad Sci USA 96:14843-14847, 1999
6. Nathan DM, Schreiber E, Fogel H, Mojsov S, Habener JF: Insulinotropic action of glucagonlike peptide-I-(7-37) in diabetic and nondiabetic subjects [see comments]. Diabetes Care 15:270-276, 1992
7. Nauck MA, Heimesaat MM, Orskov C, Holst JJ, Ebert R, Creutzfeldt W: Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest 91:301-307, 1993
8. Ahren B, Larsson H, Holst JJ: Reduced gastric inhibitory polypeptide but normal glucagon-like peptide 1 response to oral glucose in postmenopausal women with impaired glucose tolerance. Eur J Endocrinol 137:127-131, 1997
9. Naslund E, Gutniak M, Skogar S, Rossner S, Hellstrom PM: Glucagon-like peptide 1 increases the period of postprandial satiety and slows gastric emptying in obese men. Am J Clin Nutr 68:525-530, 1998
10. Lugari R, Dell'Anna C, Ugolotti D, Dei Cas A, Barilli AL, Zandomeneghi R, Marani B, lotti M, Orlandini A, Gnudi A: Effect of nutrient ingestion on glucagon-like peptide 1 (7-36 amide) secretion in human type 1 and type 2 diabetes. Horm Metab Res 32:424-428, 2000
11. Nyholm B, Walker M, Gravholt CH, Shearing PA, Sturis J, Alberti KG, Holst JJ, Schmitz O: Twenty-four-hour insulin secretion rates, circulating concentra-tions of fuel substrates and gut incretin hormones in healthy offspring of type II (non-insulin-dependent) diabetic parents: evidence of several aberrations. Diabetologia 42:1314-1323, 1999
12. Stegmayr B, Asplund K: Diabetes as a risk factor for stroke: a population perspective. Diabetologia 38:1061-1068, 1995
13. DeFronzo RA, Tobin JD, Andres R: Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 237:E214-E223, 1979
14. Pollare T, Lithell H, Selinus I, Berne C: Application of prazosin is associated with an increase of insulin sensitivity in obese patients with hypertension. Diabetologia 31:415-420, 1988